{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:52:04Z","timestamp":1793404324715,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T00:00:00Z","timestamp":1542931200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13063-018-3026-4","type":"journal-article","created":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T06:09:41Z","timestamp":1542953381000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5439-4039","authenticated-orcid":false,"given":"David S.","family":"Lawrence","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabila","family":"Youssouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00edle F.","family":"Molloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Alanio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Alufandika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Boulware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timoth\u00e9e","family":"Boyer-Chammard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Dromer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Admire","family":"Hlupeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina C.","family":"Hosseinipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Kanyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Loyse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Meya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mosepele","family":"Mosepele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Muzoora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry C.","family":"Mwandumba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiratidzo E.","family":"Ndhlovu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Niessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Schutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine E.","family":"Stott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duolao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Lalloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Meintjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabbar","family":"Jaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph N.","family":"Jarvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,23]]},"reference":[{"issue":"9513","key":"3026_CR1","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(06)68337-2","volume":"367","author":"P Braitstein","year":"2006","unstructured":"Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367(9513):817\u201324.","journal-title":"Lancet"},{"issue":"15","key":"3026_CR2","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1097\/QAD.0b013e32830007cd","volume":"22","author":"SD Lawn","year":"2008","unstructured":"Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22(15):1897\u2013908.","journal-title":"AIDS"},{"key":"3026_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/1471-2458-9-290","volume":"9","author":"B Amuron","year":"2009","unstructured":"Amuron B, Namara G, Birungi J, Nabiryo C, Levin J, Grosskurth H, et al. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health. 2009;9:290.","journal-title":"BMC Public Health"},{"issue":"12","key":"3026_CR4","doi-asserted-by":"publisher","first-page":"e28691","DOI":"10.1371\/journal.pone.0028691","volume":"6","author":"A Gupta","year":"2011","unstructured":"Gupta A, Nadkarni G, Yang WT, Chandrasekhar A, Gupte N, Bisson GP, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One. 2011;6(12):e28691.","journal-title":"PLoS One"},{"issue":"9","key":"3026_CR5","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1097\/QAD.0b013e32832be0fc","volume":"23","author":"JN Jarvis","year":"2009","unstructured":"Jarvis JN, Boulle A, Loyse A, Bicanic T, Rebe K, Williams A, et al. High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. AIDS. 2009;23(9):1182\u20133.","journal-title":"AIDS"},{"key":"3026_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1471-2334-10-67","volume":"10","author":"JN Jarvis","year":"2010","unstructured":"Jarvis JN, Meintjes G, Williams A, Brown Y, Crede T, Harrison TS. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis. 2010;10:67.","journal-title":"BMC Infect Dis"},{"issue":"8","key":"3026_CR7","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","volume":"17","author":"R Rajasingham","year":"2017","unstructured":"Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873\u201381.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"3026_CR8","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1093\/cid\/ciu057","volume":"58","author":"EC Wall","year":"2014","unstructured":"Wall EC, Everett DB, Mukaka M, Bar-Zeev N, Feasey N, Jahn A, et al. Bacterial meningitis in Malawian adults, adolescents, and children during the era of antiretroviral scale-up and Haemophilus influenzae type b vaccination, 2000-2012. Clin Infect Dis. 2014;58(10):e137\u201345.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"3026_CR9","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/S1473-3099(16)00128-6","volume":"16","author":"JN Jarvis","year":"2016","unstructured":"Jarvis JN, Harrison TS. Forgotten but not gone: HIV-associated cryptococcal meningitis. Lancet Infect Dis. 2016;16(7):756\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"3026_CR10","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1056\/NEJMoa1710922","volume":"378","author":"SF Molloy","year":"2018","unstructured":"Molloy SF, Kanyama C, Heyderman RS, Loyse A, Kouanfack C, Chanda D, et al. Antifungal combinations for treatment of cryptococcal meningitis in Africa. N Engl J Med. 2018;378(11):1004\u201317.","journal-title":"N Engl J Med"},{"issue":"5","key":"3026_CR11","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/cid\/cit794","volume":"58","author":"JN Jarvis","year":"2014","unstructured":"Jarvis JN, Bicanic T, Loyse A, Namarika D, Jackson A, Nussbaum JC, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis. 2014;58(5):736\u201345.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3026_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1086\/588792","volume":"47","author":"T Bicanic","year":"2008","unstructured":"Bicanic T, Wood R, Meintjes G, Rebe K, Brouwer A, Loyse A, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis. 2008;47(1):123\u201330.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"3026_CR13","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1097\/QAD.0b013e3283536a93","volume":"26","author":"JN Jarvis","year":"2012","unstructured":"Jarvis JN, Meintjes G, Rebe K, Williams GN, Bicanic T, Williams A, et al. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS. 2012;26(9):1105\u201313.","journal-title":"AIDS"},{"issue":"12","key":"3026_CR14","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1086\/593194","volume":"47","author":"N Longley","year":"2008","unstructured":"Longley N, Muzoora C, Taseera K, Mwesigye J, Rwebembera J, Chakera A, et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis. 2008;47(12):1556\u201361.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"3026_CR15","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1097\/QAD.0b013e328354b419","volume":"26","author":"AT Jackson","year":"2012","unstructured":"Jackson AT, Nussbaum JC, Phulusa J, Namarika D, Chikasema M, Kanyemba C, et al. A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. AIDS. 2012;26(11):1363\u201370.","journal-title":"AIDS"},{"key":"3026_CR16","volume-title":"Guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents and children","author":"WHO","year":"2018","unstructured":"WHO. Guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents and children. Geneva: World Health Organization; 2018."},{"issue":"12","key":"3026_CR17","doi-asserted-by":"publisher","first-page":"7224","DOI":"10.1128\/AAC.01698-15","volume":"59","author":"T Bicanic","year":"2015","unstructured":"Bicanic T, Bottomley C, Loyse A, Brouwer AE, Muzoora C, Taseera K, et al. Toxicity of amphotericin B deoxycholate-based induction therapy in patients with HIV-associated cryptococcal meningitis. Antimicrob Agents Chemother. 2015;59(12):7224\u201331.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"3026_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1086\/653606","volume":"51","author":"RJ Hamill","year":"2010","unstructured":"Hamill RJ, Sobel JD, El-Sadr W, Johnson PC, Graybill JR, Javaly K, et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis. 2010;51(2):225\u201332.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"3026_CR19","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.1128\/AAC.00933-12","volume":"56","author":"WW Hope","year":"2012","unstructured":"Hope WW, Goodwin J, Felton TW, Ellis M, Stevens DA. Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens. Antimicrob Agents Chemother. 2012;56(10):5303\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"3026_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/infdis\/jit164","volume":"208","author":"L O'Connor","year":"2013","unstructured":"O'Connor L, Livermore J, Sharp AD, Goodwin J, Gregson L, Howard SJ, et al. Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients. J Infect Dis. 2013;208(2):351\u201361.","journal-title":"J Infect Dis"},{"issue":"9","key":"3026_CR21","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1128\/AAC.01448-08","volume":"53","author":"PO Gubbins","year":"2009","unstructured":"Gubbins PO, Amsden JR, McConnell SA, Anaissie EJ. Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg\/kg), weekly dose (7.5 mg\/kg), or daily dose (1 mg\/kg) in peripheral stem cell transplant patients. Antimicrob Agents Chemother. 2009;53(9):3664\u201374.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"3026_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.bbmt.2005.10.010","volume":"12","author":"P Mehta","year":"2006","unstructured":"Mehta P, Vinks A, Filipovich A, Vaughn G, Fearing D, Sper C, et al. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant. 2006;12(2):235\u201340.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"3026_CR23","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/jac\/dkl141","volume":"57","author":"H Vogelsinger","year":"2006","unstructured":"Vogelsinger H, Weiler S, Djanani A, Kountchev J, Bellmann-Weiler R, Wiedermann CJ, et al. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrob Chemother. 2006;57(6):1153\u201360.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"3026_CR24","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa0903627","volume":"362","author":"S Sundar","year":"2010","unstructured":"Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med. 2010;362(6):504\u201312.","journal-title":"N Engl J Med"},{"issue":"10","key":"3026_CR25","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1086\/514341","volume":"44","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44(10):1289\u201397.","journal-title":"Clin Infect Dis"},{"key":"3026_CR26","doi-asserted-by":"crossref","unstructured":"Jarvis J, Leeme T, Molefi M, Chofle AA, Bidwell G, Tsholo K, et al. Short course high-dose liposomal amphotericin B for HIV-associated cryptococcal meningitis: A phase-II randomized controlled trial. CID. 2018; https:\/\/doi.org\/10.1093\/cid\/ciy515.","DOI":"10.1093\/cid\/ciy515"},{"key":"3026_CR27","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. Maryland: Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services; 2017."},{"issue":"26","key":"3026_CR28","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1056\/NEJMc1305981","volume":"368","author":"JN Day","year":"2013","unstructured":"Day JN, Chau TT, Lalloo DG. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013;368(26):2522\u20133.","journal-title":"N Engl J Med"},{"issue":"2","key":"3026_CR29","first-page":"189","volume":"375","author":"J Beardsley","year":"2016","unstructured":"Beardsley J, Wolbers M, Day JN. Dexamethasone in cryptococcal meningitis. N Engl J Med. 2016;375(2):189\u201390.","journal-title":"N Engl J Med"},{"issue":"11","key":"3026_CR30","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1473-3099(10)70170-5","volume":"10","author":"LJ Haddow","year":"2010","unstructured":"Haddow LJ, Colebunders R, Meintjes G, Lawn SD, Elliott JH, Manabe YC, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis. 2010;10(11):791\u2013802.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"3026_CR31","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1086\/604716","volume":"49","author":"T Bicanic","year":"2009","unstructured":"Bicanic T, Muzoora C, Brouwer AE, Meintjes G, Longley N, Taseera K, et al. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis. 2009;49(5):702\u20139.","journal-title":"Clin Infect Dis"},{"issue":"9423","key":"3026_CR32","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/S0140-6736(04)16301-0","volume":"363","author":"AE Brouwer","year":"2004","unstructured":"Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet. 2004;363(9423):1764\u20137.","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1186\/s13063-018-3155-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T00:00:00Z","timestamp":1547424000000}}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-3026-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-3026-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-3026-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T19:07:50Z","timestamp":1574449670000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-3026-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,23]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3026"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-3026-4","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13063-018-3155-9","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,23]]},"assertion":[{"value":"16 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Following publication of the original article [1], we have been notified that one of the author names was listed incorrectly. Both incorrect and correct author names are presented below. The original publication has been corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Research Ethics Committee of the London School of Hygiene and Tropical Medicine (ref. 14,355) have approved the protocol. We will not begin recruitment at any of the African sites until local ethical approval has been obtained. Any further amendments will be submitted and approved by each ethics committee.Written informed consent to enter the trial and be randomised will be obtained from participants or, in the case of those lacking capacity to consent, from family\/guardians\/persons with legal responsibility (if appropriate and in keeping with national guidance and regulations). Consent will be obtained after explanation of the aims, methods, benefits and potential hazards of the trial, and before any trial-specific procedures are performed or any blood is taken for the trial. Patients with altered mental status who are unable to consent will be enrolled into the study if their next of kin gives informed consent or assent (in keeping with appropriate national guidance and regulations) on their behalf. As soon as the patient\u2019s mental status improves consent will be obtained as above, with care taken to ensure they understand that they are free to withdraw from the study and if they do so this will not jeopardise their future care. Participants who withdraw will revert to the standard of care at the treatment site (usually amphotericin B deoxycholate and fluconazole daily for two weeks or fluconazole monotherapy for two weeks). It must be made completely and unambiguously clear that the participant (or guardian) is free to refuse to participate in all or any aspect of the trial, at any time and for any reason, without incurring any penalty or affecting their access to the standard treatment available at the recruiting site (or that of their relative). Separate consent forms will be completed for the storage and\/or genetic analysis of samples as determined by local guidelines. Original signed consent forms will be kept by the investigator and documented in the eCRF, a copy given to the participant or family and a copy placed in the participant\u2019s medical notes.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JNJ and TSH were the recipients of a Gilead Investigator Initiated Award (completed). TSH has received speaker fees from Gilead Sciences and Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"649"}}